Rit­ux­an copy­cat pass­es first piv­otal test for Am­gen, Al­ler­gan; Iron­wood and biotech spin­out name new boards

→ Am­gen and their part­ners at Al­ler­gan say their piv­otal study of a Rit­ux­an knock­off came through with pos­i­tive PK re­sults for pa­tients with rheuma­toid arthri­tis. They’re al­so run­ning a sep­a­rate piv­otal for non-Hodgkin’s lym­phoma which will go in­to their reg­u­la­to­ry fil­ing for an ap­proval.

→ New boards have been es­tab­lished for Iron­wood and its biotech spin­out Cy­cle­ri­on. In­dus­try vet Julie McHugh will chair the Iron­wood board while Cy­cle­ri­on named Mar­sha Fanuc­ci — an ex-Gen­zyme/Mil­len­ni­um ex­ec — to the head of their new board.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER